Genflow Biosciences secures administrative approval of €4M regional grant

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Genflow Biosciences Plc, a UK‑based biotechnology company developing gene therapies for age‑related diseases, said it has received administrative approval for approximately €4 million in non‑dilutive funding from the Wallonia Region of Belgium, the company said. The support follows the previously announced award and formal assent by regional authorities, with the first instalment expected by May 2026 and the three‑year package aligned with Genflow’s existing research roadmap.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE